{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:07:45Z","timestamp":1790564865924,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases and disproportionately affects women, who represent the majority of patients in real-world populations. Despite this, the representation of women in contemporary HFpEF clinical trials remains variable. In this narrative review, we examine sex distribution across major randomized trials, including TOPCAT, PARAGON-HF, EMPEROR-Preserved, and DELIVER, and compare these findings with real-world epidemiology. Women comprised approximately 44\u201352% of participants across trials, demonstrating modest discordance with real-world cohorts in which women often account for 50\u201370% of HFpEF patients. Although female enrollment in HFpEF trials has improved substantially compared with historical cardiovascular studies, important questions remain regarding the extent to which enrolled populations adequately reflect female-predominant HFpEF phenotypes, including obesity-associated HFpEF, microvascular dysfunction, and advanced multimorbidity. While some studies, particularly PARAGON-HF, suggested a potential greater treatment benefit among women, sex-specific analyses were frequently underpowered and inconsistently reported. More recent trials of sodium\u2013glucose cotransporter-2 inhibitors demonstrated consistent benefits across sexes without clear evidence of differential effect. Differences in trial eligibility criteria, including natriuretic peptide thresholds, renal function requirements, and left ventricular ejection fraction cutoffs, may further influence the representation of women and the generalizability of trial findings. These findings raise important considerations regarding external validity and generalizability of trial-derived therapies. Greater emphasis on representative enrollment and prospective evaluation of sex-specific outcomes will be essential to advancing equitable and evidence-based care in HFpEF.<\/jats:p>","DOI":"10.1097\/crd.0000000000001383","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T18:01:18Z","timestamp":1782237678000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Women in Heart Failure With Preserved Ejection Fraction Clinical Trials: Bridging the Gap Between Trial Enrollment and Real-World Disease Burden"],"prefix":"10.1097","author":[{"given":"Resha Reya","family":"Ganthan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Richmond University Medical Center, Staten Island, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rotatori","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Richmond University Medical Center, Staten Island, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"R1-20260623","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction.","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"R2-20260623","first-page":"645","article-title":"Epidemiology of heart failure with preserved ejection fraction.","volume":"136","author":"Dunlay","year":"2017","journal-title":"Circulation"},{"key":"R3-20260623","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure.","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"R4-20260623","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: from mechanisms to therapies.","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"R5-20260623","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotypic spectrum of heart failure with preserved ejection fraction.","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"R6-20260623","first-page":"401","article-title":"The emerging epidemic of heart failure with preserved ejection fraction.","volume":"10","author":"Oktay","year":"2016","journal-title":"Circ Res"},{"key":"R7-20260623","first-page":"859","article-title":"A community perspective on heart failure with preserved ejection fraction.","volume":"59","author":"Dunlay","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R8-20260623","first-page":"2631","article-title":"Outcomes in patients with heart failure with preserved ejection fraction.","volume":"60","author":"Cheng","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R9-20260623","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","article-title":"Heart failure with preserved ejection fraction.","volume":"375","author":"Redfield","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20260623","first-page":"73","article-title":"The pathophysiology of heart failure with preserved ejection fraction.","volume":"130","author":"Borlaug","year":"2014","journal-title":"Circulation"},{"key":"R11-20260623","first-page":"1885","article-title":"A novel paradigm for heart failure with preserved ejection fraction.","volume":"34","author":"Paulus","year":"2013","journal-title":"Eur Heart J"},{"key":"R12-20260623","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R13-20260623","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R14-20260623","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jacc.2018.02.070","article-title":"Participation of women in clinical trials supporting FDA approval of cardiovascular drugs.","volume":"71","author":"Scott","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R15-20260623","first-page":"e008133","article-title":"Enrollment of older patients, women, and racial\/ethnic minorities in contemporary heart failure clinical trials.","volume":"7","author":"Tahhan","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R16-20260623","first-page":"540","article-title":"Enrollment of women in cardiovascular clinical trials.","volume":"121","author":"Kim","year":"2010","journal-title":"Circulation"},{"key":"R17-20260623","first-page":"275","article-title":"The role of sex-specific results reporting in cardiovascular disease.","volume":"15","author":"Blauwet","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R18-20260623","first-page":"1015","article-title":"Representation of women in randomized clinical trials of cardiovascular disease prevention.","volume":"303","author":"Melloni","year":"2010","journal-title":"JAMA"},{"key":"R19-20260623","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R20-20260623","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"R21-20260623","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R22-20260623","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"R23-20260623","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study.","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"R24-20260623","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology and clinical implications.","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur Heart J"},{"key":"R25-20260623","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1093\/eurheartj\/ehu254","article-title":"Association between renal function and cardiovascular outcomes in HFpEF.","volume":"35","author":"Gori","year":"2014","journal-title":"Eur Heart J"},{"key":"R26-20260623","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction.","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"R27-20260623","first-page":"2679","article-title":"Why are women more likely than men to develop HFpEF?.","volume":"124","author":"Scantlebury","year":"2011","journal-title":"Circulation"},{"key":"R28-20260623","first-page":"e495","article-title":"Prevalence and correlates of coronary microvascular dysfunction in HFpEF.","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"R29-20260623","first-page":"338","article-title":"Efficacy of sacubitril\/valsartan relative to a prior decompensation: the PARAGON-HF trial.","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"R30-20260623","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap.","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"R31-20260623","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction.","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"R32-20260623","first-page":"46","article-title":"Leptin\u2013aldosterone\u2013neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure with a preserved ejection fraction.","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R33-20260623","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamacardio.2017.4987","article-title":"Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction.","volume":"3","author":"de Boer","year":"2018","journal-title":"JAMA Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000001383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:33:36Z","timestamp":1787747616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000001383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001383","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}